Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells - TREAT-ME-1 - a phase I, first in human, first in class trial

PURPOSE: This phase I, first in human, first in class clinical study aimed at evaluating the safety, tolerability and efficacy of treatment with genetically modified mesenchymal stromal cells (MSC) in combination with ganciclovir (GCV). MSC_apceth_101 are genetically modified autologous MSCs used as...

Descripción completa

Detalles Bibliográficos
Autores principales: von Einem, Jobst C., Peter, Sylvia, Günther, Christine, Volk, Hans-Dieter, Grütz, Gerald, Salat, Christoph, Stoetzer, Oliver, Nelson, Peter J., Michl, Marlies, Modest, Dominik P., Holch, Julian W., Angele, Martin, Bruns, Christiane, Niess, Hanno, Heinemann, Volker
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655186/
https://www.ncbi.nlm.nih.gov/pubmed/29113291
http://dx.doi.org/10.18632/oncotarget.20964

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655186/
https://www.ncbi.nlm.nih.gov/pubmed/29113291
http://dx.doi.org/10.18632/oncotarget.20964

Ejemplares similares